Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-06 | Dr. Siegel served as a director since November 2017. He most recently served as Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson, which he joined in 2003, and on the Executive Committees and Boards of the Biotechnology Innovation Organization and the Alliance for Regenerative Medicine. |
| 2019-04-05 | Dr. Siegel received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University... The Board believes that Dr. Siegel’s medical training and 36 years of experience in biotechnology qualify him to serve as a member of our Board. |
| 2020-04-03 | Dr. Siegel has served as a director since November 2017. He most recently served as Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson, which he joined in 2003, and on the Executive Committees and Boards of BIO and the Alliance for Regenerative Medicine. Prior to joining Johnson & Johnson, Dr. Siegel had a distinguished 20-year career at the Food and Drug Administration ("FDA") in positions of increasing responsibility, including directing the office responsible for reviewing and approving therapeutic biologics. Dr. Siegel currently co-chairs the National Academies Forum on Regenerative Medicine. In addition, Dr. Siegel serves as a director of a privately held biopharmaceutical company. He received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University. |
| 2021-04-02 | Dr. Siegel received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University. |
| 2022-04-08 | He received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University. |
| 2023-04-17 | He received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University. |
Data sourced from SEC filings. Last updated: 2026-02-03